| BC050112 |
Colon metastatic carcinoma tissue array, 23 cases 63 cores, replaced by CO726
|
US Biomax
|
|
231.00 € |
|
Publication
|
| KD808 |
Mid advanced stage kidney cancer and metastatic carcinoma tissue array, including TNM and pathology grade, 80 cases 80 cores
|
US Biomax
|
|
231.00 € |
|
Publication
|
| OM601 |
Metastatic carcinoma of epiploon tissue array, 60 cases 60 cores
|
US Biomax
|
|
266.00 € |
|
Publication
|
| BR451 |
Breast cancer tissue microarray with matched normal adjacent tissue and metastatic lymph nodes, 45cases 45 cores, with ER, PR and P53 IHC results
|
US Biomax
|
|
160.00 € |
|
Publication
|
| LY803 |
Lymphatic metastatic adenocarcinoma tissue array, 80 cases 80 cores
|
US Biomax
|
|
266.00 € |
|
Publication
|
| PR953 |
Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replaced by PR954
|
US Biomax
|
|
456.00 € |
|
Publication
|
| BRM961 |
Breast cancer tissue array containing primary and matched metastatic tumors (in lymph nodes) and adjacent normal breast tissue, 48 casea 96 cores
|
US Biomax
|
|
314.00 € |
|
Publication
|
| ME207 |
High density (69 cases 207 cores), multiple primary melanoma, metastatic and normal tissues array
|
US Biomax
|
|
456.00 € |
|
Publication
|
| ST8013 |
Stomach cancer metastatic tissue array, 40 cases 80 cores
|
US Biomax
|
|
231.00 € |
|
Publication
|
| ES806 |
Metastatic esophageal cancer tissue array, 40 cases 80 cores
|
US Biomax
|
|
231.00 € |
|
Publication
|
| MTU951 |
Multiple tumor tissue array covering 40 types of all the common benign, malignant and metastatic entities, 40 cases 95 cores
|
US Biomax
|
|
225.00 € |
|
Publication
|
| BR1005a |
Breast cancer and matched metastatic carcinoma of lymph node tissue array, including TNM, clinical stage and pathology grade, 50 cases 100 cores, replacing BR1005; ihc Anti-Actin confirmed
|
US Biomax
|
|
296.00 € |
|
Publication
|
| LY802 |
Lymph node metastatic squamous cell carcinoma tissue array, 80 cases 80 cores
|
US Biomax
|
|
266.00 € |
|
Publication
|
| PR952 |
Prostate adenocarcinoma tissue array with matched normal adjacent tissue and metastatic bones, 40 cases 95 cores, with TNM and Gleason scores, replaced by PR953
|
US Biomax
|
|
314.00 € |
|
Publication
|
| BR954 |
Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, replacing BR953; ihc
|
US Biomax
|
|
429.00 € |
|
Publication
|
| ME1004a |
Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM and clinical stage, 100 cases 100 cores, replacing ME1004; ihc Anti-Actin confirmed
|
US Biomax
|
|
296.00 € |
|
Publication
|
| SM208 |
Small intestine cancer, metastatic lymph nodes and normal tissue high density tissue microarray, 69 cases 208 core, with stage and grade data
|
US Biomax
|
|
456.00 € |
|
Publication
|
| ES2001 |
Esophagus squamous cell carcinoma and metastatic carcinoma tissue array, with adjacent tissue and adjacent normal tissue, including TNM and pathology grade, 120 cases 200 cores
|
US Biomax
|
|
516.00 € |
|
Publication
|
| MT2081 |
Multiple organ metastatic cancer tissue array, 19 organ 104 cases 208 cores
|
US Biomax
|
|
456.00 € |
|
Publication
|
| BR1005 |
Breast cancer and matched metastatic carcinoma of lymph node, 50 cases 100 cores, no overlaps with BR1001 or BR1004
|
US Biomax
|
|
314.00 € |
|
Publication
|
| LC951 |
Lung cancer tissue array with normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 40 cases 95 cores
|
US Biomax
|
|
456.00 € |
|
Publication
|
| PR951 |
Prostate adenocarcinoma tissue array with matched normal adjacent tissue and metastatic bones, 40 cases 95 cores, with TNM and Gleason scores, replaced by PR952; ihc Anti-PCNA confirmed
|
US Biomax
|
|
487.00 € |
|
Publication
|
| BR953 |
Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, replacing BR952
|
US Biomax
|
|
456.00 € |
|
Publication
|
| ME1004 |
Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM, 100 cases 100 cores, replacing ME1003
|
US Biomax
|
|
314.00 € |
|
Publication
|
| PR956 |
Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replacing PR955; ihc Anti-Actin confir
|
US Biomax
|
|
487.00 € |
|
Publication
|
| CO952 |
Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases 95 cores, replacing CO951; ihc Anti-Cytokeratin (CK) confi
|
US Biomax
|
|
429.00 € |
|
Publication
|
| MET961 |
Metastatic cancer tissue array, 48 cases 96 cores
|
US Biomax
|
|
225.00 € |
|
Publication
|
| BR10010a |
Breast cancer and matched metastatic carcinoma tissue array, including TNM and pathology grade, with ER, PR and Her-2 (neu) IHC results, 50 cases 100 cores, replacing BR10010; ihc Anti-Actin confirme
|
US Biomax
|
|
296.00 € |
|
Publication
|
| LC817 |
Lung cancer tissue array with matched lymph node metastatic tissue, including TNM, clinical stage and pathology grade, 40 cases 80 cores; ihc Anti-Actin confirmed
|
US Biomax
|
|
258.00 € |
|
Publication
|
| OV951 |
Ovary cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 38 cases 95 cores,
|
US Biomax
|
|
456.00 € |
|
Publication
|
| BR952 |
Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores
|
US Biomax
|
|
456.00 € |
|
Publication
|
| ME1003 |
Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, including TNM and clinical stage, 100 cases 100 cores, replaced by ME1004
|
US Biomax
|
|
266.00 € |
|
Publication
|
| PR955 |
Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replacing PR954
|
US Biomax
|
|
558.00 € |
|
Publication
|
| CO951 |
Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases 95 cores
|
US Biomax
|
|
456.00 € |
|
Publication
|
| MET181 |
Metastatic cancer tissue array, 18 cases 18 cores
|
US Biomax
|
|
166.00 € |
|
Publication
|
| BR10010 |
Breast cancer and matched metastatic carcinoma tissue array, including TNM and pathology grade, 50 cases 100 cores, replacing BR1004
|
US Biomax
|
|
314.00 € |
|
Publication
|
| KD951 |
Kidney cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage, pathology grade and survival data, 32 cases 95 cores
|
US Biomax
|
|
456.00 € |
|
Publication
|
| OV804 |
Ovarian metastatic carcinoma tissue array, 80 cases 80 cores
|
US Biomax
|
|
266.00 € |
|
Publication
|
| BR951 |
Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER PR p53 IHC results and survival data, 31 cases 95 cores, to be replaced by BR95
|
US Biomax
|
|
456.00 € |
|
Publication
|
| ME1001 |
Malignant melanoma, metastatic malignant melanoma and benign nevus tissue array, replaced by ME1003, 100 cases 100 cores
|
US Biomax
|
|
266.00 € |
|
Publication
|
| PR954 |
Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases 95 cores, replaced by PR955
|
US Biomax
|
|
456.00 € |
|
Publication
|
| CO726 |
Metastatic colon carcinoma tissue array, 24 cases 72 cores, replacing BC050112
|
US Biomax
|
|
266.00 € |
|
Publication
|
| ME207b |
High density (69 cases 207 cores), multiple primary melanoma, metastatic and normal skin tissue array block
|
US Biomax
|
|
40 981.00 € |
|
Publication
|
| TH809a |
Thyroid metastatic carcinoma tissue array with normal thyroid tissue as control, 40 cases 80 cores, replacing TH809; ihc Anti-Actin confirmed
|
US Biomax
|
|
296.00 € |
|
Publication
|